| Recruiting | Phase II Open-label Trial of Neoadjuvant Immunochemotherapy for Resectable Non-metastatic Colon cancER: NICER NCT05870800 | Baylor College of Medicine | Phase 2 |
| Recruiting | French Assessment of MRD by Liquid Biopsies in Stage III CRC Patients (FRENCH.MRD.CRC) NCT06287814 | University Hospital, Montpellier | — |
| Suspended | Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients NCT05062889 | Gruppo Oncologico del Nord-Ovest | Phase 2 |
| Recruiting | Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease NCT05174169 | NRG Oncology | Phase 2 / Phase 3 |
| Completed | Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Ca NCT04164069 | Anne Noonan | Phase 1 |
| Terminated | Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Can NCT04044430 | University of California, San Francisco | Phase 1 |
| Recruiting | Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer NCT03803553 | Massachusetts General Hospital | Phase 3 |
| Active Not Recruiting | Oxaliplatin Adjuvant Chemotherapy After Curative Resection of Primary Colon Cancer NCT04416490 | Boryung Pharmaceutical Co., Ltd | — |
| Unknown | Real-world Retrospective Data Analysis of Adjuvant Therapy for Patients With Stage II-III Colon Cancer After R NCT03958435 | Second Affiliated Hospital, School of Medicine, Zhejiang University | — |
| Terminated | Avelumab Plus 5-FU Based Chemotherapy as Adjuvant Treatment for Stage 3 MSI-High or POLE Mutant Colon Cancer NCT03827044 | Royal Marsden NHS Foundation Trust | Phase 3 |
| Active Not Recruiting | LEAn Body Mass Normalization of OXaliplatin Based Chemotherapy NCT03255434 | Institut du Cancer de Montpellier - Val d'Aurelle | Phase 2 |
| Completed | Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer NCT03154190 | Stanford University | N/A |
| Unknown | Prognostic Value of the Immunoscore® Colon Test for Disease Free Survival Stratification in Stage III Patients NCT03422601 | GERCOR - Multidisciplinary Oncology Cooperative Group | — |
| Unknown | Maintenance Tegafur-uracil Versus Observation Following Adjuvant Oxaliplatin-based Regimen in Patients With St NCT02836977 | Kaohsiung Medical University Chung-Ho Memorial Hospital | N/A |
| Completed | Exercise and Colon Cancer NCT02250053 | Abramson Cancer Center at Penn Medicine | N/A |
| Completed | Low Glycemic Load Diet in Patients With Stage I-III Colon Cancer NCT02129218 | Case Comprehensive Cancer Center | N/A |
| Unknown | Cytokine-induced Killer Cell Immunotherapy for Surgical Resected Stage III Colorectal Cancer Patients After Ch NCT02280278 | Sun Yat-sen University | Phase 3 |
| Completed | Immunotherapy With CEA(6D) VRP Vaccine (AVX701) in Patients With Stage III Colorectal Cancer NCT01890213 | Duke University | Phase 1 |
| Terminated | Polyphenon E in Treating Patients With High-Risk of Colorectal Cancer NCT01606124 | Mayo Clinic | Phase 2 |
| Completed | Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer NCT01191684 | City of Hope Medical Center | Phase 1 |
| Completed | RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors NCT01158274 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Quality of Life and Survivorship Care in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC) NCT01126346 | Wake Forest University Health Sciences | N/A |
| Completed | Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorecta NCT00551421 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Resveratrol in Treating Patients With Colorectal Cancer That Can Be Removed By Surgery NCT00433576 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Suberoylanilide Hydroxamic Acid, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Progressi NCT00138177 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Sorafenib, Cetuximab, and Irinotecan in Treating Patients With Advanced or Metastatic Colorectal Cancer NCT00134069 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidne NCT00101348 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors NCT00089362 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer NCT00087191 | National Cancer Institute (NCI) | N/A |
| Terminated | Combination Chemotherapy and Bevacizumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent NCT00070122 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Underg NCT00079274 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer NCT00028496 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating Patients With NCT00025337 | National Cancer Institute (NCI) | Phase 3 |
| Completed | SU5416 and Irinotecan in Treating Patients With Advanced Colorectal Cancer NCT00005818 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Fluorouracil Plus Leucovorin With or Without Oxaliplatin in Treating Patients With Stage II or Stage III Colon NCT00004931 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu NCT00004074 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Combination Chemotherapy in Treating Patients With Stage III Colon Cancer NCT00003835 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer NCT00019006 | National Cancer Institute (NCI) | Phase 1 |